Your search for evid returned 4 results

Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.

Treatment with dupilumab led to a significant 30% reduction in moderate or severe acute COPD exacerbations.

Tofersen is an investigational antisense medicine that reduces the synthesis of SOD1 protein production.

Rezzayo is expected to be available in the summer of 2023.